The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Managing toxicities associated with bispecific T-cell engaging therapies in patients with myeloma
Wee Joo Chng, MB ChB, MRCP, MRCPath, PhD, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, discusses cytokine release syndrome (CRS), the primary short-term toxicity associated with the administration of T-cell engaging therapies in patients with multiple myeloma (MM), and emphasizes the importance of early recognition and intervention to manage it effectively. Prof. Chng notes that while neurotoxicity can occur, it is relatively rare, especially in Asian patients. In the long term, managing infections through vaccination and careful monitoring is critical. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
